124 result(s)
Home Medical Affairs
Get access to the latest news and research in medical affairs with this comprehensive portal. Stay up-to-date with the latest clinical trials, studies, and developments in the medical field. Explore a variety of resources to enhance your knowledge and stay informed.
Contact Us Confirmation
Solicite la visita de uno de nuestros delegados de GSK- Confirmación
Impact of varying lung function threshold on clinical remission in asthma with FF/UMEC/VI: CAPTAIN post hoc analysis.
Poster PA1199 from ERS 2024 presenting post hoc analysis of clinical remission from the CAPTAIN study.
Han, M.K., Vanfleteren, L.E.G.W., Kolterer, S. et al. Striving for Stability in Patients with COPD: A New Way Forward?. Adv Ther (2024)
ERS 2024 supplemental symposium report
ERS 2024 - COPD Portfolio Symposium
Full recording of Striving for Disease Stability in COPD. Giving patients more if their best days. Co-Chairs by Meilan K. Han and Dave Singh Prof. MeiLan Han: Prof of Medicine, Divison of Pulmonary and Critical Care - University of Michigan, USA. Prof. Dave Singh: Prof of Respiratory Pharmacology, University of Manchester, UK. Dr. Lowie Vanfleteren: Head of the COPD Center - Sahgrenska University Hospital, Goffenburg, Sweden.
CAPTAIN Clinical Remission ERS Poster Mod-Sev Audio for poster PA 1197
Audio to support poster PA1197 from ERS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
CAPTAIN Clinical Remission ERS lung function; audio for poster PA1199
Audio to support poster PA1197 from ERS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
CAPTAIN Clinical Remission ERS baseline; audio for poster PA1198
Audio to support poster PA1197 from ERS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
ERS 2024 Asthma Symposium - Summary
Can we break through the therapeutic ceiling in severe asthma? Prof. Celeste Porsbjerg - Professor of Severe Asthma - Bispebjerg Hospital, Denmark
ERS 2024 Asthma Symposium
Full symposium recording of Can we break through the therapeutic ceiling in severe asthma? Prof. Celeste Porsbjerg - Professor of Severe Asthma - Bispebjerg Hospital, Denmark
Assessment of the components of clinical remission with moderate–severe asthma after 24–52 weeks of treatment: CAPTAIN post hoc analysis
Poster PA1198 from ERS 2024 presenting post hoc analysis of clinical remission from the CAPTAIN study.
Characteristics of patients meeting the components of clinical remission: CAPTAIN post hoc analysis.
Poster PA1197 from ERS 2024 presenting post hoc analysis of clinical remission from the CAPTAIN study.
Characteristics of severe eosinophilic asthma
Severe asthma with eosinophilic phenotype is a distinct phenotype of severe asthma. This phenotype is characterized by airway inflammation, increased blood/sputum eosinophil (EOS) concentrations, poor asthma control, and increased rate of exacerbations.
Impact of varying health status thresholds on disease stability in COPD with FF/UMEC/VI: IMPACT post hoc analysis.
Halpin MGD, et al. By demonstrating the effect of inhaled therapies on measures of health status (SGRQ and CAT) according to different thresholds, it may be possible to better assess disease stability in clinical practice. Disease stability should be considered an ambitious, practical and realisable treatment goal for patients with COPD, with the potential to guide patient management. Poster PA1173
Impact of varying lung function thresholds on disease stability in COPD with FF/UMEC/VI: IMPACT post hoc analysis.
Halpin MGD, et al. By demonstrating the effect of inhaled therapies on different lung function thresholds, it may be possible to better assess disease stability in clinical practice. Disease stability should be considered an ambitious, practical and realisable treatment goal for patients with COPD, with the potential to guide patient management. Presentation OA4653
Towards disease stability in COPD management: patient perspectives
Brooke M, et al. Patient advocacy advisors highlight disease stability as a desirable treatment goal for COPD, driven by patient aspirations and clinical characteristics. Personalisation of treatment strategies and patient care underpins the achievement and maintenance of disease stability resulting in improvements to the quality of life for patients living with COPD. Poster PA1171
Real-world assessment of clinical remission in asthma with biologics Howarth P, et al. Poster PA2182
ERS Poster
ERS 2024 SOOTHE Study Poster
Smith JA, et al. Prior and concomitant medication use in patients with refractory chronic cough: post-hoc analysis of SOOTHE. ERS 2024. Poster No. PA319
Expert video describing disease stability
Video by Prof Dave Singh and Prof MeiLan Han describing disease stability and what it might mean for patients.
Refractory Chronic Cough Patient Story video
Short Video of RCC patient sharing the burden of this disease
RCC Mechanism of Disease Loop Video
Short video looking at the pathophysiology of refractory chronic cough
Medical COPD portfolio symposium summary video_ERS 2024
Short video with the faculty, summarising the key takeaways of the symposium.
Talking Head Video
Short Talking Head Videos outlining the unmet need in Refractory Chronic Cough and the importance of early recognition
CAPTAIN Study sub-group analysis video
The CAPTAIN study provides robust evidence to support, and better tailor, the use of triple therapy in asthma using a precision medicine approach. In this video, Professor Ian Pavord presents a sub-group analysis from the CAPTAIN study exploring the impact of type 2 biomarker status on outcomes.
Clinical Remission in Asthma
A collection of materials addressing Clinical Remission in asthma which is an ambitious but attainable treatment goal for patients with asthma irrespective of disease severity and treatment history
AAAAI 2024 CAPTAIN study post-hoc Clinical Remission oral presentation (key take aways video)
Video recording of Prof. Oppenheimer presenting key takeaways from the CAPTAIN clinical remission post hoc analysis results from AAAAI 2024
Audio for the FULFIL Study Post Hoc Analysis Poster P630 at ATS 2024
Audio of Prof. David Singh presenting the FULFIL Study Post Hoc Analysis at ATS 2024
What is Clinical Remission concept video
Video recording of Prof. Oppenheimer providing an overview of clinical remission in asthma
CAPTAIN Study main results video
The CAPTAIN study provides robust evidence to support, and better tailor, the use of triple therapy in asthma using a precision medicine approach. In this video, Professor Ian Pavord presents the main results from the CAPTAIN study
Audio for the FULFIL Study Post Hoc Analysis Poster P630 at ATS 2024
Audio of Prof. David Singh presenting the FULFIL Study Post Hoc Analysis at ATS 2024
GAA May Webinar_ Lavoie Pre-recorded video
GSK-GAA Webinar 2024: Optimising evidence through a patient-centred approach
GAA May Webinar_ Panel Pre-recorded video
GSK-GAA Webinar 2024: Panel Discussion
MoD video (localisable version)
Short video summarising the IL-5 biology and recent evidence surrounding this science, as well as the cells impacted directly and indirectly by the IL-5 pathway.
uUTI Mechanism of Disease Video
The CAPTAIN study provides robust evidence to support, and better tailor, the use of triple therapy in asthma using a precision medicine approach. In this video, Professor Ian Pavord presents the main results from the CAPTAIN study
GAA May Webinar_ Yorgancıoğlu Pre-recorded video
GSK-GAA Webinar 2024: Personalized Asthma Care in the Clinic - Applying the latest evidence
NMA in Triple Therapy summary
For FF/UMEC/VI, the NMA suggest favourable efficacy compared with other single-inhaler triple therapies.
CAPTAIN Study Clinical Remission Poster: ATS 2024
Poster from ATS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
NMA in Triple Therapy: Class comparison data in COPD
FF/UMEC/VI versus triple and dual bronchodilator therapies
The EMAX trial
Asthma is a heterogeneous disease and its management is multifactorial; many patients often remained uncontrolled despite treatment. HCPs have a critial role in identifying and managing patients who are not adequately controlled, which involves: -Regular discussions with patients -Recognition of symptoms and exacerbation risks -Continuous assessment of treatment -Reassessment of treatment and follow-up
Inhaled molecules for COPD treatment
How does molecule pharmacology correlate with clinical efficacy and safety? Pharmacological properties of inhaled respiratory molecules are critical to ensure the best possible clinical outcomes.
Network Meta-analysis (NMA) introduction for Triple Therapy
Comparing efficacy of triple therapies among patients with COPD. Multiple RCTs have demonstrated the benefit of triple over dual inhaled therapy in improving lung function and reducing the risk of exacerbation for patients with COPD
Inhalers in Respiratory Medicine > Unmet Need
In this section the symptom burden and unmet needs of patients with COPD are discussed, as well as the importance of correct inhaler technique and the impact of multiple inhaler therapy.
Inhalers in Respiratory Medicine >Patient Benefits
What are the key considerations affecting inhaler choice, from a patient and physician perspective?
Inhalers in Respiratory Medicine >Clinical Efficacy
Clinical efficacy of inhaled therapy delivered via the Ellipta inhaler. As well as ease of use, and fewer patients making an error with their inhaler, treatments are needed that show clinical efficacy.
RWE interactive map 2024
An interactive map displaying RWE studies in asthma, CRSwNP, EGPA, COPD and HES
EAACI 2024: Medical booth IL-5 digital infographic
Interactive pdf explaining the impact of IL-5 beyond eosinophils on cells. including its role in a variety of pathophysiological processes
AAAAI 2024 CAPTAIN study post-hoc Clinical Remission oral presentation (full video)
Video recording of Prof. Oppenheimer presenting key takeaways from the CAPTAIN clinical remission post hoc analysis results from AAAAI 2024
CAPTAIN Study Clinical Remission Poster: ATS 2024
Poster from ATS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
Jackson, D.J. et al. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. NEJM (2024)
NEJM publication of the phase III SWIFT studies investigating the efficacy and safety of depemokimab in severe asthma.
Depemokimab efficacy/safety in patients with asthma on medium/high- dose ICS: the Phase IIIA randomised SWIFT-1/2 studies.
Presentation from ERS 2024 of the phase III SWIFT studies investigating the efficacy and safety of depemokimab in severe asthma.
Depemokimab PK/PD in the 52-week randomised double-blind multicentre Phase III SWIFT-1 trial.
Presentation OA3647 from ERS 2024 of the PK/PD assessment of depemokimab in the phase IIIA SWIFT-1 trial.
Enhanced in vitro potency of depemokimab for interleukin-5 inhibition versus mepolizumab.
Presentation OA3644 from ERS 2024 of an in vitro study assessing the relative potency of depemokimab and mepolizumab.
Patient video: "Living with unstable COPD: A patient's story"
This is a short video summarising the patient burden of living with COPD.
Patient video: "Looking forward: patient's hopes for COPD care"
a short video summarising the patient hopes for COPD care
Patient video: "Disease stability: a patient's perspective"
a short video summarising the patient perspective of disease stability
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. Prof. Philippe Gevaert
Full results from our positive ANCHOR-1 and ANCHOR-2 phase III clinical trials, with late-breaking data published in The Lancet.
2025 AAAAI/WAO Joint Congress
Full results from our positive ANCHOR-1 and ANCHOR-2 phase III clinical trials, with late-breaking data published in The Lancet.
ATS 2025
Full results from our positive ANCHOR-1 and ANCHOR-2 phase III clinical trials, with late-breaking data published in The Lancet.
Benefit of Early Versus Delayed Intervention With Mepolizumab in Patients With Severe Uncontrolled Asthma (SUA): A Retrospective Cohort Study. Corbridge T, et al.
Early initiation of mepolizumab can reduce the burden of asthma exacerbations, OCS usen and hospitalisations in patients with SUA, and highlights the need for timely identification and treatment of these patients
Mepolizumab Is Efficacious in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With One or Multiple Prior Nasal Polyps (NP) Surgeries: SYNAPSE Outcomes Han JK, et al.
Mepolizumab significantly improves outcomes in patients with CRSwNP with 1 or mutliple prior NP surgeries
The Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on the Pharmacokinetics and Safety of Camlipixant in Healthy Participants Satia I, et al.
American Academy of Allergy, Asthma & Immunology Poster 714
Low Adherence to Current Biologic Therapies in Asthma: Insights From a Retrospective Cohort Analysis of Claims Data Kwiatek J,et al.
Adherence to biologics among US patients with asthma is lower than previously reported, highlighting the eed for improved adherence monitoring.
Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study. Pavord I, et al.
This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in pediatric, adolescent, and adult patients with severe asthma. The safety analysis was consistent with previous reports, with ni emerging safety concerns.
ANCHOR-1 and ANCHOR-2 Studies of Depemokimab in Chronic Rhinosinusitis With nasal Polyps
Study Objective and Design of ANCHOR 1 and 2 studies.
SWIFT-1 and SWFT-2 Studies od Depemokimab in Svere Asthma
Overall Study objective and Design of SWIFT-1 and SWIFT-2 studies
Efficacy and Safety of Twice-Yearly Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): The Phase III Randomized, Double-Blind, Placebo-Controlled Replicate ANCHOR-1/2 Trials. Han JK, et all
Full results from our positive ANCHOR-1 and ANCHOR-2 phase III clinical trials, with late-breaking data presented at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in San Diego and simultaneously published in The Lancet.
Twice-Yearly Depemokimab Demonstrates an Acceptable Safety Profile in a 12-Month Interim Analysis of the AGILE Phase III Open-Label Extension Study Jackson DJ, et al.
Long term depemokimab was well tolerated with safety and efficacy profiles consistent with those in SWIFT-1/2 studies and demonstrating sustained efficacy for patients remaining on depemokimab
Depemokimab Reduces Exacerbations in Patients With Type 2 Asthma Characterized by Blood Eosinophils Across a Range of Blood Eosinophil and IgE Levels: SWIFT Subgroup Analyses Bernstein D, et al.
Twice-yearly depemokimab demonstrates consistend exacerbation reduction in patients with asthma across a range of baseline type 2 biomarkers measurements
Mepolizumab Improves Patient Reported Outcomes and Reduces Treatment Burden in Patients With Chronic Rhinosinusitis With Nasal Polyps: A Real-World Chart Review Study. Edgecomb AG, et al
In real-world practice, mepoluzimab substantially improves SNOT-22 score treatment burden, and symptoms in patients with CRSwNP
Greater Odds of Clinical Remission With Mepolizumab Versus Placebo in Severe Asthma: A 24-Week Individual Patient Data Meta-Analysis of RCTs Gould S, et al.
Patients with severe asthma not receiving mOCS are more likely to achive clinical remission components when receiving mepolizumab compered with placebo
The Impact of Itraconazole, a Strong CYP3A4 Inhibitor, on the Pharmacokinetics and Safety of Camlipixant in Healthy Participants Peters A, et al.
American Academy of Allergy, Asthma & Immunology Poster 714
Mepolizumab Reduces Systemic Corticosteroid (SCS)-Related Toxicities Compared to Chronic SCS Use in Patients With EGPA. Pongdee T, et al
Patients with EGPA in a real)world setting, mepolizumab treatment significantly reduces the overall occurrende of acute and chronic SCS-related toxicities and reduces HRU compered with patients receiving chronic SCS treatment
Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype
This study investigates the efficacy of mepolizumab in patients with late-onset severe eosinophilic asthma and fixed obstruction3. Results suggest that mepolizumab treatment leads to clinical improvement and reduces indices of airway tissue remodeling, indicating a potential disease-modifying effect.
Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils Buchheit KM, et al.
Interleukin-5 (IL-5) is a key driver of eosinophils, key effector cells in the pathophysiology in many upper and lower airway diseases. However, recent evidence suggests that eosinophil-depletion alone may not account for all of the therapeutic effects of anti-IL-5 therapy and that IL-5 may also contribute to disease independently of its effects on eosinophils.
Eosinophils and tissue remodeling: Relevance to airway disease
Eosinophils play a cardinal role in airway remodeling both in health and disease, driving epithelial homeostasis and extracellular matrix turnover, impacting patient outcomes in severe asthma and CRSwNP.
GSK Medical Affairs - Contact
Contacte con el centro de información, solicite la visita de un delegado o el contacto por el departamento médico, Notifique de una sospecha de reacción adversa
Load more
Thank you for your query. We're sorry, but we don't find information about this topic:
Here are some steps that you can take to improve the accuracy of your search:
- Check the spelling of your search.
- Try a different wording.
- Reset or review the filters applied (if filters were used to perform this search).
- Check the accuracy of your search terms.
- Try using multiple keywords to narrow down your search.
- Try using synonyms or related words to broaden your search.
